PDS Biotech Announces Updated Data From The IMMUNOCERV Phase 2 Clinical Trial Evaluating Versamune HPV With Chemoradiation To Treat Locally Advanced Cervical Cancer Will Be Presented During An Oral Presentation At The 2024 Astro Annual Meeting
PDS Biotech Announces Updated Data From The IMMUNOCERV Phase 2 Clinical Trial Evaluating Versamune HPV With Chemoradiation To Treat Locally Advanced Cervical Cancer Will Be Presented During An Oral Presentation At The 2024 Astro Annual Meeting
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune HPV (formerly PDS0101) with chemoradiation to treat locally advanced cervical cancer will be presented during an oral presentation at the 2024 ASTRO Annual Meeting being held in Washington, DC, and virtually September 29 through October 2, 2024.
普迪思生物技術公司（納斯達克股票代碼：PDSB）（「PDS Biotech」或「公司」）是一家專注於改變免疫系統如何靶向和殺死癌症及開發感染病疫苗的後期免疫療法公司。今天宣佈，IMMUNOCERV 2期臨床試驗的更新數據將在2024年ASTRO年會上進行口頭報告，該報告將於2024年9月29日至10月2日在華盛頓特區和虛擬視覺下進行。該臨床試驗評估了Versamune HPV（前稱PDS0101）聯合化療放射治療，用於治療局部晚期宮頸癌。
Details of the presentation are as follows:
演示的詳細信息如下:
Date: Tuesday, October 1, 2024, 2:50-3:00 p.m. ET
Session title: SS 34 - GYN 2: Strategies and Innovations of Clinical Trials in Gynecologic Cancers
Presentation title: 298 - IMMUNOCERV Phase II Trial Combining the HPV-Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer
Presenting author: Adam Grippin, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
日期：2024年10月1日，美國東部時間下午2:50-3:00
會議議題：SS 34- GYN2：婦科癌症臨床試驗的策略和創新
報告主題：298- IMMUNOCERV 2期試驗中結合HPV特異性T細胞免疫療法PDS0101和化療放療治療局部晚期宮頸癌
主講人：Adam Grippin, 萬博士. 米德蘭德安德森癌症中心
